Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.

Guardado en:
Detalles Bibliográficos
Autores principales: João M. Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N. Ooft, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, August Vidal, Emile Voest, Lodewyk F. A. Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/fa274e19e6774a2dbd7ad05e9103dbab
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/fa274e19e6774a2dbd7ad05e9103dbab

Ejemplares similares